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ABSTRACT 
Cocrystals are multicomponent system in which one component is Active Pharmaceutical Ingredient (API) and another is called coformer. So 
coformer selection is one of the main challenge in cocrystal development which is compatible with API. A general approach to coformer selection is 
by “tactless” cocrystal screening, whereby a predetermined library of pharmaceutically acceptable/approved compounds is used to attempt 
cocrystallization. In cocrystal development one of the approach of coformer selection is based on trial and error. Other approaches are 
supramolecular synthon approach which utilizes Cambridge Structural Database (CSD) to effectively prioritize coformers for crystal form screening, 
Hansen solubility parameter and knowledge of hydrogen bonding between coformer and API. In this review, all the parameters are explain and 
correlate with each other and with cocrystal formation 
Keywords: Cocrystal, Coformer, Supramolecular synthon, Cambridge structural database, Hansen solubility parameter. 
 
INTRODUCTION 
Pharmaceutical cocrystals have attracted phenomenal interest in 
recent years for their potential for improving the physicochemical 
properties of drug substances[1,7]. Apart from offering potential 
improvements in solubility, dissolution rate, bioavailability and 
physical stability, pharmaceutical cocrystals can enhance other 
essential properties of the APIs such as flowability, chemical 
stability, compressability and hygroscopicity[2,7]. Cocrystals are 
homogeneous solid phases containing two or more neutral 
molecular components in a crystal lattice with defined 
stoichiometry, which are solids at room temperature and are held 
together by weak interactions, mainly hydrogen bonding[1,8]. In 
cocrystals at least one component is molecular and a solid at room 
temperature i.e. coformer and forms a supramolecular synthon with 
a molecular or ionic API. The first cocrystal synthesized was 
quinhydrone which is a 1:1 cocrystal between benzoquinone and 
hydroquinone. 
Comparison Of Cocrystal And Other Solid Forms 
 
 
Fig. 1: Comparison of different solid forms of API[33] 
 
Cocrystal versus Salts, Solvates, Solid dispersions, Hydrates 
Salt formation is generally directed at a single acidic and basic 
functional group and cocrystal can simultaneously address multiple 
functional groups in a single reaction, including acidic, basic and 
nonionizable molecules [34,35,36]. In the formation of salts transfer 
of hydrogen atom occurs and it does not occur in the formation of 
cocrystals. 
If one component is liquid at room temperature then the crystals are 
designated as solvates and if both components are present in solid 
form then crystals are designated as cocrystals[3,37]. In solvates one 
component is present in a liquid form so they are less stable as 
compared to cocrystal. 
When solvent present in solvates is water then it is termed as 
hydrates [3]. 
cocrystal synthesis 
Cocrystals contain two or more components which are held together 
by supramolecular synthons. In order to obtain cocrystal, functional 
groups capable of forming supramolecular hetero or homosynthons 
should be present in the API and coformer. In supramolecular 
synthons approach, steps involved in developing cocrystals are as 
follows 1) Choosing the target molecule(API) 2) Finding the 
complementary functional groups which is capable of forming a 
hydrogen bond.(coformer selection) 3) Methods of Preparation. 
One of the main challenges in pharmaceutical cocrystal development 
is the selection of coformers that are compatible with a particular 
API. A general approach to coformer selection is by “tactless” 
cocrystal screening, whereby a predetermined library of 
pharmaceutically acceptable/approved compounds is used to 
attempt cocrystallization. The lead cocrystal candidate with superior 
physicochemical and pharmacological properties can then be 
developed into a dosage form [4]. 
In another word we can say that typical crystal form selection 
process comprises two stages of development after a target API 
molecule has been selected: (1) discover as many pharmaceutical 
crystal forms as possible (2) then examine the physicochemical 
properties of the newly discovered crystal forms. At the stage of 
crystal form discovery, two primary approaches are used. The more 
straightforward approach is largely based on trial-and-error. The 
alternative approach for crystal form discovery is the 
supramolecular architecture which recognizes supramolecular 
synthons as a design tool and can be more selective, time-efficient, 
and cost effective. The supramolecular synthon approach uses 
crystal engineering to carefully analyze the relevant supramolecular 
arrangements that an API might exhibit by utilizing the Cambridge 
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Structural Database (CSD) and effectively prioritizes all possible 
guest molecules for crystal form screening of drugs and another 
parameter is hydrogen bonding. 
The supramolecular synthon approach is a statistical analysis that 
utilizes the Cambridge Structural Database (CSD) to effectively 
prioritize coformers for crystal form screening if an appropriate 
supramolecular heterosynthon can be identified. Supramolecular 
heterosynthons, typically involving hydrogen bonds between 
different but complementary groups, are exemplified by carboxylic 
acid/amide and carboxylic acid/aromatic nitrogen supramolecular 
heterosynthons. 
(1)  (2)  
Fig. 2: Supramolecular Heterosynthons (1)carboxylic 
acid/amide (2)carboxylic acid/ aromatic nitrogen[2] 
 
Another parameter is Hansen solubility parameters study which was 
used to investigate whether the miscibility of a drug and coformer is 
matching with the theoretical data. 
So, supramolecular synthon approach, Cambridge Structural 
Database (CSD), hydrogen bonding and Hansen solubility 
parameters these are most important parameter for selection of 
coformer in the cocrystal formation. In this review, all the 
parameters are explain and correlate with each other and with 
cocrystal formation. 
Supramolecular Synthon Approach 
A pharmaceutical cocrystal can be designed by crystal engineering 
with the intention to improve the solid-state properties of an API 
without affecting its intrinsic structure. Crystal engineering affords a 
paradigm for rapid development of pharmaceutical cocrystals. It can 
be defined as an application of the concepts of supramolecular 
chemistry to the solid state with particular emphasis upon the idea 
that crystalline solids are actual manifestations of self-assembly 
[2,38,39,40]. Crystal engineering relies on the basic principles of 
supramolecular chemistry, chemistry beyond the molecule, in 
developing novel entities by manipulating the non-covalent 
intermolecular interactions. Hydrogen bonding, metal coordination, 
van der Waals forces, hydrophobic forces, electrostatic effects and 
pi-pi interactions are some of the interactions which are commonly 
encountered in this regard[2,41]. Crystal engineering is also based 
on understanding the basic behind formation of synthons using non 
covalent interaction. The term synthon was coined by Corey in the 
context of organic chemistry and defined as “structural units within 
supermolecules which can be formed and/or assembled by known 
or conceivable intermolecular interactions”. A supramolecular 
synthon is a pattern that is composed of molecular and 
supramolecular elements. When crystal patterns repeat regularly, 
the pattern of interactions can be called a supramolecular synthon. 
Supramolecular synthons are further categorized into: 
(a) supramolecular homosynthon: composed of identical self-
complementary functionalities 
(b)supramolecular heterosynthons: composed of different but 
complementary functionalities. 
Single-component or compounds containing the functional groups 
can be sustained by supramolecular homosynthons whereas; 
supramolecular heterosynthons can dominate in the presence of 
other competing functional groups. 
This concept may be better explained with the help of following 
figure. 
 
(a)     (b) 
 
Fig. 3: Types of supramolecular synthons[14] 
(a) Supramolecular homosynthon [In this case between two 
carboxylic acid groups] 
(b) Supramolecular heterosynthon [In this case between carboxylic 
acid and amide group] 
Example of the supramolecular synthon which is commonly used are 
given below includes 
(1) Homosynthon formed between carboxylic acid dimer (2) 
Heterosynthon formed between carboxylic acid group and pyridine 
group (3) Homosynthon formed between amide dimer (4) 
Heterosynthon formed between carboxylic acid group and amide 
group (5) Heterosynthon formed between alcohol and ether group. 
Generally heterosynthons are more robust than homosynthons. e.g. 




The most common supramolecular synthons in Crystal Engineering are:- 
Fig. 4: Most common supramolecular synthons in Crystal Engineering [2] 
 
 
HANSEN SOLUBILITY PARAMETER 
Miscibility of a drug and coformer, as predicted by Hansen Solubility 
Parameters (HSPs), can indicate cocrystal formation and guide 
cocrystal screening. Predicting the miscibility of cocrystal 
components using solubility parameters can guide the selection of 
potential coformers prior to exhaustive cocrystal screening work. 
Cocrystals are homogeneous solid phases containing two or more 
neutral molecular components in a crystal lattice with defined 
stoichiometry, which are solids at room temperature and are held 
together by weak interactions, mainly hydrogen bonding. By 
definition, cocrystals are miscible systems at a molecular level. It is 
therefore hypothesized that an indication of the miscibility of the 
component molecules in the solid state could predict the likelihood 
of cocrystal formation[1]. 
The concept of a solubility parameter was introduced by Hildebrand 
and Scott, who proposed that materials with similar values would be 
miscible [1,43]. The Hansen solubility parameter (HSP) model, 
which was developed later, is based on the concept of dividing the 
total cohesive energy into individual components (dispersion, polar 
and hydrogen bonding)[1,22] In pharmaceutical sciences, HSPs have 
been used to predict the miscibility of a drug with 
excipients/carriers in solid dispersions[1,44]. Further, it has been 
suggested that HSPs could predict the compatibility of 
pharmaceutical materials, and their use is recommended as a tool in 
the pre-formulation and formulation development of 
tablets[1,45,46]. HSPs have been widely used to predict liquid–liquid 
miscibility, miscibility of polymer blends, surface wettability, and the 
adsorption of pigments to surfaces [1,23] 
The solubility parameters (i.e. cohesion energy parameters) can be 
used to predict the physicochemical properties such as solubility, 
melting point, etc. of a material [1,45].  
The cohesive energy is the sum of the forces (van der Waals 
interactions, covalent bonds, hydrogen bonds and ionic bonds) that 
hold the material intact [1]. The cohesive energy per unit volume is 
termed the cohesive energy density (CED). The CED can be used to 
calculate the solubility parameter (δ) based on regular solution 
theory restricted to non-polar systems, as follows[1,43] 
δ=(CED)0.5=(ΔEV/Vm)0.5 
where EV is the energy of vaporization, and Vm is the molar volume. 
δ is measured in units of (J/cm3)
(1) 
0.5, or (cal/cm3)0.5
Attempts have been made to extend the Hildebrand and Scott 
approach to include polar systems and strongly interacting species. 
One of the most widely accepted approaches, using HSPs, proposes 
that the total force of the various interactions can be divided into 
partial solubility parameters, i.e. dispersion (δ
. 
d), polar (δp) and 
hydrogen bonding (δh). These partial solubility parameters 
represent the possibility of intermolecular interactions between 
similar or different molecules. The total solubility parameter (δ t
δ
), 
also called the three-dimensional solubility parameter, can be 
defined as follows [1]:  
t  = (δ2 d+ δ2 p + δ2 h)0.
Various methods have been used to estimate the HSPs of a material 
such as various theoretical and experimental methods based on 
solubility, calorimetry, sublimation, vaporization, inverse gas 
chromatography and group contribution methods [1,23]. 
5 (2) 
As other method requires practical knowledge, the group 
contribution method is a commonly used theoretical method that 
only requires knowledge of the compound’s chemical structure to 
calculate the HSPs[1,48].The partial solubility parameters can be 
calculated using the combined group contribution methods of Van 




where i is the structural group within the molecule, Fdi is the group 
contribution to the dispersion forces, Fpi is the group contribution 
to the polar forces, Fhi is the group contribution to the hydrogen 
bonding energy, and Vi is the group contribution to the molar 
volume.  
Based on the prediction of miscibility, laboratory screening for 
cocrystals was conducted using thermal methods and liquid-assisted 
grinding (LAG). The discovered cocrystals were scaled-up and 
preliminarily characterized using high performance liquid 
chromatography (HPLC), thermal methods, Raman spectroscopy and 
powder X-ray diffraction (PXRD). 
In summary, most of the cocrystal-forming coformers which is under 
consideration show miscibility with the drug but not all miscible 
drug/coformer systems form cocrystals due to many reasons, such 
as lack of hydrogen bonding complementarity, preferred packing 
patterns, conformational flexibility, molecular shape and size, and 
stability. Alternatively, though appear less likely, immiscible systems 
can form cocrystals as a result of strong intermolecular interactions 
and packing. Miscibility of the components is necessary for cocrystal 
formation. 
CAMBRIDGE STRUCTURAL DATABASE 
The Cambridge Structural Database (CSD) is a repository for small 
molecule crystal structures. Scientists use single-crystal x-ray 
crystallography to determine the crystal structure of a compound. 
Once the structure is solved, information about the structure is 
saved but in CSD scientists can search and retrieve structures from 
the database. Scientists can use the CSD to compare existing data 
with that obtained from crystals grown in their laboratories. The 
information can also be used to visualize the structure in a variety of 
software such as atoms, powdercell etc. This is particularly important 
for analytical reasons because it facilitates the identification of 
phases present in a crystalline powder mixture without the need for 
growing crystals. 
Many of the small molecules are organic compounds that can 
potentially act as medical drugs, and CSD is used for structural 
comparisons among these related molecules that can suggest new 
leads for drug design. 
The information stored in the CSD for each entry can be considered 
in three classes. Firstly, there is the text-based (and sometimes 
numeric) information, containing the bibliography (i.e. full literature 
reference, where appropriate), chemical names and formulae, some 
experimental information about the crystal structure determination 
procedure, and any other information that may be available (e.g. 
compound’s use, colour and shape of crystals, etc.). Secondly, there 
is chemical connectivity information in the form of a 2D structural 
diagram –which is the basis of much of the sophisticated search 
mechanisms for the CSD System. Thirdly, there is the 
crystallographic information, consisting of unit cell dimensions and 
space group, and atomic coordinates. In this third category where 
the true value of the Database lies.  
The rational design of cocrystals is usually based on supramolecular 
Synthons [50]. But this has some limitations which are usually 
handled by cocrystal screening, a trial-and-error procedure [51]. For 
practical applications, development costs will depend on the number 
of screening experiments needed before a suitable cocrystal former 
is found. It would therefore be important to identify further factors 
beyond synthon matching that influence the success or failure of 
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screening experiments. So, it is important to find such factors by the 
statistical analysis of data on cocrystals from the Cambridge 
Structural Database [52]. 
Cocrystal Database Creation 
The CSD searches for ordered, error-free organic crystal structures 
(at least one C atom, only C, H, N, O, S, P, F, Cl, Br, or I atoms allowed). 
Duplicates and unreliable or incomplete structures are filter out. 
Then remaining structures are exported from the CSD to mol2 files, 
which are used for further processing and calculations. Sum 
formulas, formal charges (as stored in the CSD), are calculated for 
each residue [5].  
Calculation of Molecular Descriptors 
The complete set of quantitative structure-activity relationship 
(QSAR) type descriptors available in software tools used to 
characterize the molecules, without any prior consideration of their 
importance in cocrystal formation. The descriptors include simple 
atom, bond and group counts, hydrogen bond donor and acceptor 
counts, size and shape descriptors, surface area descriptors (with 
partitioned and charge weighted variants), and molecular 
electrostatic descriptors[5]. 
Statistical Analysis 
Molecules that found in the same cocrystal should combine into 
pairs. As a first approximation, descriptors grouped in pairs, that is, 
only one descriptor per molecule consider at a time. If a particular 
pair of descriptors refers to molecular properties that influence 
cocrystal formation, then the descriptors are expected to assume 
favourable combinations of values more frequently than 
unfavourable ones. Consequently, pairs of descriptors that indicate 
some form of complementarity should be correlated. To find such 
correlations, correlation coefficients should calculate for all possible 
pairs of descriptors. The distribution of descriptor values among the 
molecules is far from a normal distribution, which limits the 
usability of the most common statistical parameters, such as mean 
value and standard deviation. Therefore, nonparametric statistical 
descriptors, which are meaningful irrespective of the shape of the 
distributions, can be used. Distributions summarize by median, 
lower quartile, and upper quartile values, rather than by mean and 
standard deviation. (Median is the value that “splits” a data set such 
that 50% of the data values are lower and 50% are higher than the 
median. Quartiles are defined analogously as values that are higher 
than 25% (lower quartile) and 75% (upper quartile) of the data set, 
respectively). In addition to the more common Pearson’s correlation 
coefficient (r, based on mean and standard deviation), Spearman’s 
nonparametric correlation coefficient (F, based on the ranking of 
values) can be calculated for each molecular descriptor pair. If a 
significant negative correlation of F found between the number of 
heavy (i.e., non-hydrogen) atoms in both molecules, this would 
indicate a preference of small molecules to cocrystallize with large 
ones, because crystals of a large host molecule with an awkward 
shape that cannot pack efficiently and a small guest molecule that 
fills the voids inside or between the host molecules, since these 
molecule pairs showed a distinct behaviour and we are interested in 
cocrystal formation of molecules without major packing 
frustration[5]. 
Molecular Polarity 
The strongest correlations found are related to the polarity of the 
molecules. The positive sign of the correlation coefficients suggests 
that molecules preferably form cocrystals with partners of similar 
polarity. Molecular polarity is not a rigorously defined term, so a 
number of descriptors can be associated with it. 
The highest correlation relates the fractional polar volumes (FPV) of 
the cocrystallized molecules. FPV is defined as the fraction of the 
molecular volume that belongs to polar atoms (N, O, S atoms, and H 
atoms bonded to N, O, or S). A simpler alternative to using FPV is the 
descriptor FNO, which is obtained by dividing the total number of N 
and O atoms by the number of heavy atoms in the molecule. FNO still 
shows a relatively strong correlation, and it can be easily calculated 
from the molecular formula.(i.e., those with lower values of 
globularity), which are predominantly planar molecules. Shape 
correlation means that molecules of a flat shape tend to form 
cocrystals with other flat molecules, the stronger tendency of 
elongated molecules to cocrystallize with partners of similar shape. 
Globularity is a shape descriptor that relates the surface area of a 
molecule to its volume. It is small for molecules with a smooth 
surface, while bumps and hollows of the molecular shape increase 
its value.This shape relationship appears to be stronger for smooth 
molecules [5]. 
Hydrogen Bond 
The success of cocrystal design by utilizing hydrogen-bonded 
supramolecular synthons clearly shows the importance of hydrogen 
bond in forming cocrystals. After metal coordination bonds and ionic 
interactions (e.g. dipole-dipole) the strongest interactions in crystal 
engineering are hydrogen bonds. Due to the strength, directionality, 
and ubiquitous presence of hydrogen bonds in organic molecules, it 
is also termed as the ‘key-interaction’ in crystal engineering. 
For most pharmaceutical cocrystal structures, hydrogen bonds take 
an important role in directing intermolecular recognition between 
an API and a coformer molecule. A graph-set notation system 
introduced by was used widely to describe and label hydrogen bond 
motifs [2,46]. 
 In the graph-set system four principal motifs are used: chains (C), 
dimers (D), rings (R), and intramolecular hydrogen bonds (S), as 
descriptors of hydrogen-bonded molecular solids. Additionally, the 
following guidelines were proposed to facilitate the design of 
hydrogen bonded solids: (1) all good proton donors and acceptors 
are used in hydrogen bonding; (2) if six-membered ring 
intramolecular hydrogen bonds can form, they will usually do so in 
preference to forming intermolecular hydrogen bonds (3) the best 
proton donors and acceptors remaining after intramolecular 
hydrogen-bond formation, form intermolecular hydrogen bonds to 
one another [2]. With self-complementary hydrogen bond donor and 
acceptor, the formation of carboxylic acid homosynthon through 
C=O··H–O hydrogen bond is very common. Another widely studied 
homosynthon is amide homodimer, forming a cocrystal through 
C=O··H–N hydrogen bond. Apart from homosynthons, some 
favourable heterosynthons such as carboxylic acid-pyridine and 
carboxylic–amide. Counting donors and acceptors is insufficient to 
describe their complementarity. The formation of synthons is 
governed by the strength of hydrogen bonds between cocrystal 
formers rather than by the number of available groups. 
CONCLUSION 
Coformer selection is one of the main challenge in cocrystal 
development. Primary approach is tactless screening of the coformer 
from library which is of GRAS status. Another approach is 
supramolecular synthon approach which utilizes Cambridge 
structural database for statistical analysis of data. A detail 
understanding of the supramolecular chemistry of functional group 
present in given molecule is the prerequisite for cocrystal design 
because it facilitates selection of suitable cocrystal former.  
The HSPs can predict the miscibility and cocrystal formation by 
using group contribution method and to calculate partial solubility 
parameters and Van Krevelen–Hoftyzer, Bagley and Greenhalgh 
approaches to predict miscibility.  
This approach is effective in predicting miscibility but all coformer 
which is predicted may or may not be miscible so, this is only 
theoretical approach which would be useful for short listing 
potential coformers prior to complex laboratory screening 
experiments, leading to greater efficiency in cocrystal screening 
programs. The use of Hydrogen bond, synthon and HSPs may assist 
in design and analysis of cocrystals. In general though prediction of 
whether cocrystallization will occur is not possible and must, at 
present, be answered empirically.  
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